Silevertinib is an investigational new drug that is being evaluated by Black Diamond Therapeutics for the treatment of glioblastoma and non-small cell lung cancer. It is a EGFR protein tyrosine kinase inhibitor.
Investigational drug
Silevertinib
All data from the card 9
- Other names
- RVU-120
- CAS Number
- 2607829-38-7
- PubChem CID
- 156071569
- IUPHAR/BPS
- 13371
- UNII
- RP9F537KVY
- KEGG
- D13300
- Formula
- C30H30ClFN6O2
- Molar mass
- 561.06 g·mol−1
- 3D model (JSmol)
- Interactive image
Read next
GefitinibMedication used for cancer
BrigatinibALK inhibitor for treatment of non-small-cell lung cancer
MobocertinibSmall molecule tyrosine kinase inhibitor
AmivantamabMonoclonal antibody
OsimertinibChemical compound, used as a medication to treat lung cancer
Epidermal growth factor receptorTransmembrane proteinText from Wikipedia, CC BY-SA 4.0 · Source article